First AD

Second AD

 Anthony, when do you think we should be measuring MRD?

 I think it also depends which regimen you

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Revolution of Therapy in Acute Lymphoblastic Leukemia

Peer Exchange

Time Points in the Assessment of MRD

Molecular Cytogenetic Risk Stratification in ALL

Pediatric-Inspired Regimens in ALL

How Age Affects Treatment Approaches in ALL

Effective Novel Agents in Upfront Treatment of ALL

Considerations of Cytoreduction in ALL

Revolutionizing the Treatment of Ph+ ALL with TKIs

Therapeutic Approaches in Philadelphia-like ALL

Role of MRD Testing in Adult Acute Lymphocytic Leukemia

Monitoring for Relapse in Acute Lymphoblastic Leukemia

Blinatumomab for Patients with MRD-Positive ALL

The Evolving Role of Transplant in ALL

CAR T: Dominant Therapy for B-Cell ALL

Examining the Toxicities of CAR T-cell Therapy

Acute Lymphocytic Leukemia: What's Next

Approaching the Management of Philadelphia-Negative ALL

Treatment Algorithms for Philadelphia-Negative ALL 

Ph-Negative ALL: Establishing Blinatumomab's Role in Therapy

Blinatumomab: Safety Data in Ph-Negative ALL 

Establishing MRD's Role in ALL Management 

Allogeneic Transplant at First Remission of ALL

Selecting a Novel Therapy for Relapsed/Refractory ALL 

When to Use Inotuzumab Ozogamicin for Adult ALL 

Evaluating CAR T Therapy in Acute Lymphoblastic Leukemia

Future Treatment Strategies in Adult ALL